Assay Detail
Functional
CHEMBL1659942
Review assay metadata, readout intent, target linkage, and publication context from the same page.
Antiviral activity against HIV1 expressing protease L10I/G48V/I54V/A71V/I84V/L90M mutant infected in human MT4 cells selected at 5 uM of saquinavir by MTT assay
9
Total Activities
9
Compounds Tested
1
Activity Types
0
Assay Parameters
Assay Information
| Assay Type | Functional |
| Organism | Human immunodeficiency virus 1 |
| Cell Type | MT4 |
| Confidence | 1 — Organism |
| Curated By | Autocuration |
Target
Human immunodeficiency virus 1 (CHEMBL378) ↗| Type | ORGANISM |
| Organism | Human immunodeficiency virus 1 |
Publication
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Activity Statistics
| Type | Count | Avg pChEMBL | Best pChEMBL |
|---|---|---|---|
| EC50 | 9 | 7.23 | 8.52 |
Compounds Tested
| Compound | Name | Phase | Activities | Best pChEMBL |
|---|---|---|---|---|
| CHEMBL1323 | DARUNAVIR | 4.0 | 1 | 8.52 |
| CHEMBL571882 | — | — | 1 | 7.70 |
| CHEMBL222559 | TIPRANAVIR | 4.0 | 1 | 7.66 |
| CHEMBL577560 | — | — | 1 | 7.34 |
| CHEMBL729 | LOPINAVIR | 4.0 | 1 | 6.92 |
| CHEMBL116 | AMPRENAVIR | 4.0 | 1 | 6.75 |
| CHEMBL1163 | ATAZANAVIR | 4.0 | 1 | 6.68 |
| CHEMBL584 | NELFINAVIR | 4.0 | 1 | 6.29 |
| CHEMBL114 | SAQUINAVIR | 4.0 | 1 | - |
Activity Data
| Compound | Name | Type | Rel. | Value | Units | pChEMBL |
|---|---|---|---|---|---|---|
| CHEMBL1323 | DARUNAVIR | EC50 | = | 3.0 | nM | 8.52 |
| CHEMBL571882 | — | EC50 | = | 20.0 | nM | 7.70 |
| CHEMBL222559 | TIPRANAVIR | EC50 | = | 22.0 | nM | 7.66 |
| CHEMBL577560 | — | EC50 | = | 46.0 | nM | 7.34 |
| CHEMBL729 | LOPINAVIR | EC50 | = | 120.0 | nM | 6.92 |
| CHEMBL116 | AMPRENAVIR | EC50 | = | 180.0 | nM | 6.75 |
| CHEMBL1163 | ATAZANAVIR | EC50 | = | 210.0 | nM | 6.68 |
| CHEMBL584 | NELFINAVIR | EC50 | = | 510.0 | nM | 6.29 |
| CHEMBL114 | SAQUINAVIR | EC50 | > | 1000.0 | nM | - |